Dr. Nabil Hajji, a research scientist at the Dassault Systèmes Center of Excellence at LIU, is directing directing the Translational Systems Medicine Platform for Brain Tumors, a multidisciplinary initiative to develop new biomarkers, therapies, and personalized medicine for patients with brain tumors. Hajji is a world-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in several types of cancer.
